?Effect of Allicin derivatives capsule in treatment of patients with new Coronavirus

Early Phase 1

• Conditions: Condition 1: COVID-19. Condition 2: COVID-19.; COVID-19, virus not identified; COVID-19, virus identified; U07.2; U07.1

• Registration Number: IRCT20200610047722N1
• Lead Sponsor: Hossein Nik Tale

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Patients with RT-PCR positive for SARS-CoV-2 , clinical sign and symptoms (fever, cough and myalgia) and CT scan indicate COVID-19 positive.
Age 18-70
Sign consent form

Exclusion Criteria

History of allergic reaction to Allicin
History of allergic reaction to Garlic or Onion
History of low blood pressure or gastrointestinal tract bleeding
Low blood pressure and the beginning of study (lower that 120/80 mmHg)
Patients with immune deficiency disorders (patients undergo chemotherapy, organ or bone marrow transplants and patients with autoimmune disease)
No need to use ventilator during the study
Unable to swallow the oral medication
Pregnancy
Breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified